Abstract
Acute stroke can be classified as ischemic, hemorrhagic, or both and result in the occurrence of multiple pathophysiological processes. These pathophysiological events develop over the subsequent hours to days, as the original core of the infarct develops into the surrounding penumbral area (1, 2). Initial cell death results from the deprivation of blood supply to the brain. However, a significant portion of the brain damage occurs later when secondary deleterious mechanisms come into play (2). The recent progress made in defining the mechanisms involved in the pathophysiology of stroke will probably lead to the identification of new strategies for intervention in the ischemic cascade. Therefore, it becomes increasingly important to initially consider how these new therapeutics may be delivered into the target tissue in brain and secondly to speculate on new strategies that would target ischemic brain tissue.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Dirnagl U, Iadecola, C, Moskowitz, MA, Pathobiology of ischemic stroke: an integrated view, Trends Neurosci 1999; 22: 391–397.
Lee JM, Zipfel GJ, Choi DW, The changing landscape of ischemic brain injury mechanisms, Nature 1999; 399: A7 - A14.
Suckling AJ, Rumsby MG, Bradbury M.W.B., Eds., The blood-brain barier in health and disease ( Ellis Horwood, Chichester,) 1986.
Brightman MW, Ultrastructure of brain endothelium. In M. W. B. Bradbury, Physiology and pharmacology of the blood-brain barrier, Springer-Verlag, Berlin, 1992: pp. 1–22.
Pardridge W, Peptide drug delivery to the brain. ( Raven Press, New York ) 1991.
Mitic LL, Anderson JM, Molecular architecture of tight junctions. Annu. Rev. Physiol. 1998; 60: 121–142.
Kroll RA, Neuwelt EA, Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means, Neurosurgery 1998; 42: 1083–1099.
Pardridge W, Peptide drug delivery to the brain. J Cereb Blood Flow Metab 1997: 17; 713–731.
Pardridge WM, Vector mediated drug delivery to the brain, Adv Drug Deliv Rev 1999; 36: 299–321.
Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Jones RS, Neuwelt EA, A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery, Am J Neuroradiol 1999; 20: 217–222.
Mahoney MJ, Saltzman WM, Controlled release of proteins to tissue transplants for treatment of neurodegenerative disorders, J Pharm Sci 1996; 85: 1276–1281.
Benoit JP, Faisant N, Venier-Julienne MC, Menei P, Development of microspheres for neurological disorders: basics to clinical applications, J Controlled Release 65 (2000) 285–296.
Chang PL, Van Raamsdonk JM, Hortelano G, Barsoum SC MacDonald NC, Stockley TL, In vivo delivery of heterologous proteins by microencapsulated recombinant cells, Trends Biotechnology 1999; 17: 78–83.
Yan Q, Matheson C, Sun J, Radeke MJ, Feinstein SC, Miller JA, Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with Trk receptor expression, Exp Neurol 1994; 127: 23–36.
Kuroiwa T, Ting P, Martinez H, Klatzo I, The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion, Acta Neuropathol 1985; 68: 122–129.
Jones TH, Morawetz RB, Crowell RM, Marcoux FW, Fitzgibbon SJ, De Girolami U, Ojemann RG, Threshold of focal cerebral ischemia in awake monkeys, J Neurosurg 1981; 54: 773–782.
Kraig RP, Petito CK, Plum F, Pulsinelli WA, Hydrogen ions kill at concentrations reached in ischemia. J Cereb Blood Flow Metab 1987; 7: 379–386.
Mun-Bryce S, Rosenberg GA, Matrix metalloproteinases in cerebrovascular disease, J Cereb Blood Flow Metab 1998; 18: 1163–1172.
Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ, A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther 1997; 8: 729783.
Maysinger D, Morinville A, Drug delivery to the nervous system. Trends Biotechnol 1997; 15: 410–418.
Imaizumi S, Woolworth V, Fishman RA, Chan PH, Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. Stroke 1990; 21: 1312 1317.
Stanimirovic DB, Markovic M, Micic DV, Spatz M, Mrsulja BB, Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion oxidative stress in gerbil brain. Neurochem Res 1994; 19: 1473–1478.
Khaw BA, Torchilin VP, Vural I, Narula J, Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med 1995; 1: 1195–1198.
Torchilin VP, Narula J, Halpern E, Khaw BA, Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposome: factors influencing targeted accumulation in the infarcted myocardium. Biochim Biophys Acta 1996; 1279: 75–83.
Glorioso, JC, Goins WF, Meaney CA, Fink DJ, DeLuca NA, Gene transfer to brain using herpes simplex virus vectors. Ann Neurol 1994; 35 Suppl: S28–S34.
Lawrence MS, Sun GH, Kunis DM, Saydam TC, Dash R, Ho DY, Sapolsky RM, Steinberg GK, Overexpression of the glucose transporter gene with a herpes simplex viral vestor protects striatal neurones against stroke. J Cereb Blood Flow Metab 1996; 16: 18 1185.
Yenari MA, Minami M, Sun GH, Meier Ti, Kunis DM, McLauglin JR, Ho DY, Sapolsky RM, Steinberg GK, Calbindin d28k Over-expression protects striatal neurones from transient focal cerebral ischemia. Stroke 2001; 32: 1028–1035.
Hoehn B, Ringer, TM, WU L, Giffard RG, Sapolsky RM, Steinberg GK, Yenari MA, Overexpression of HSP72 after induction of experimental stroke protects neurones from ischemic damage. J. Cereb Blood Flow Metab. 2001; 21: 1303–1309.
Linnick MD, Zahos P, Geschwnd MD, Federhoff HJ, Expression of bc1–2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 1995; 26: 1670–1674.
Phillips RG, Lawrence MS, Ho DY, Sapolsky RM, Limitations in the neuroprotective potential of gene therapy with BCL-2. Brain Res 2000; 859: 202–206.
Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF, In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999; 285: 1569–1572.
Jansen EM, Solberg L, Underhill S, Wilson S, Cozzari C, Hartman BK, Faris PL, Low WC, Transplantation of fetal neocortex ameliorates sensorimotor and locomotor deficits following neonatal ischemic-hypoxic brain injury in rats. Exp Neurol 1997; 147: 487–497.
Li Y, Chen J, Chopp M, Adult bone marrow transplantation after stroke in adult rats. Cell Transplantation 2001; 10: 31–40.
Li Y, Chen J, Wang L, Lu M, Chopp M, Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology 2001; 56: 1666–1672.
Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Chopp M, Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001; 32: 1005–1011.
Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, Sanchez-Ramos J, Chopp M, Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001; 32: 2682–2688.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Petty, M.A., Lo, E.H. (2002). Targeting Brain Trauma and Stroke. In: Muzykantov, V., Torchilin, V. (eds) Biomedical Aspects of Drug Targeting. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-4627-3_18
Download citation
DOI: https://doi.org/10.1007/978-1-4757-4627-3_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5312-4
Online ISBN: 978-1-4757-4627-3
eBook Packages: Springer Book Archive